Cargando…

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer

PD1 inhibition is effective in patients with metastatic urothelial cancer (mUC), yet a large fraction of patients does not respond. In this study, we aimed to identify a blood-based immune marker associated with non-response to facilitate patient selection for anti-PD1. To this end, we quantified 18...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rijnders, Maud, Robbrecht, Debbie G. J., Oostvogels, Astrid A. M., van Brakel, Mandy, Boormans, Joost L., Aarts, Maureen J. B., Balcioglu, Hayri E., Hamberg, Paul, Voortman, Jens, Westgeest, Hans M., Lolkema, Martijn P., de Wit, Ronald, van der Veldt, Astrid A. M., Debets, Reno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947015/ https://www.ncbi.nlm.nih.gov/pubmed/35976415 http://dx.doi.org/10.1007/s00262-022-03250-0

Ejemplares similares

Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer
por: Mendelaar, Pauline A. J., et al.
Publicado: (2022)

CD45RA(+)CCR7(−) CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
por: Kunert, Andre, et al.
Publicado: (2019)

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020)

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
por: Siddiqui, Imran, et al.
Publicado: (2016)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy
por: Mahajan, Shweta, et al.
Publicado: (2023)

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
por: de With, Mirjam, et al.
Publicado: (2021)

T Cells Expressing a TCR-Like Antibody Selected Against the Heteroclitic Variant of a Shared MAGE-A Epitope Do Not Recognise the Cognate Epitope
por: Saeed, Mesha, et al.
Publicado: (2020)

Lack of B and T cell reactivity towards IDH1(R132H) in blood and tumor tissue from LGG patients
por: Weenink, Bas, et al.
Publicado: (2019)

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial
por: Rutten, V. C., et al.
Publicado: (2023)

Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression
por: Salhi, Youssra, et al.
Publicado: (2023)

Rintatolimod (Ampligen(®)) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program
por: el Haddaoui, Hassana, et al.
Publicado: (2022)

Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries—Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients
por: de Koning, Willem, et al.
Publicado: (2023)

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
por: Mutsaers, Pim, et al.
Publicado: (2021)

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody
por: Saeed, Mesha, et al.
Publicado: (2016)

Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report
por: de Joode, Karlijn, et al.
Publicado: (2023)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Intratumoral Niches of B Cells and Follicular Helper T Cells, and the Absence of Regulatory T Cells, Associate with Longer Survival in Early-Stage Oral Tongue Cancer Patients
por: Phanthunane, Chumut, et al.
Publicado: (2022)

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial
por: Stockem, C.F., et al.
Publicado: (2023)

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets
por: Straetemans, Trudy, et al.
Publicado: (2012)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies
por: de Joode, K., et al.
Publicado: (2023)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition
por: de Joode, K., et al.
Publicado: (2021)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
por: Ishii, Akiko, et al.
Publicado: (2020)

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
por: Kobayashi, Takashi, et al.
Publicado: (2020)

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
por: McNally, Michelle A., et al.
Publicado: (2021)

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
por: Hammerl, Dora, et al.
Publicado: (2021)

The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs
por: Yildirim, Hilin, et al.
Publicado: (2023)

Author Correction: NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
por: Hasegawa, Moto, et al.
Publicado: (2020)

Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder
por: van den Tempel, Nathalie, et al.
Publicado: (2018)

Functional and Structural Plasticity of Brain in Elite Karate Athletes
por: Duru, Adil Deniz, et al.
Publicado: (2018)

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder
por: van Doeveren, Thomas, et al.
Publicado: (2020)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022)

Tumor-induced remote ECM network orientation steers angiogenesis
por: Balcioglu, Hayri E., et al.
Publicado: (2016)

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
por: Bins, Sander, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ukfii8ttokl60l08cligkl1uoi